Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. cut its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 96.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,791 shares of the company’s stock after selling 1,470,550 shares during the quarter. Baillie Gifford & Co. owned about 0.06% of Sutro Biopharma worth $90,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Sutro Biopharma by 7.7% during the third quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock worth $6,426,000 after acquiring an additional 132,015 shares during the last quarter. State Street Corp boosted its position in shares of Sutro Biopharma by 5.2% in the third quarter. State Street Corp now owns 1,647,162 shares of the company’s stock worth $5,699,000 after buying an additional 81,855 shares during the period. Bank of Montreal Can purchased a new stake in shares of Sutro Biopharma in the third quarter worth about $2,852,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Sutro Biopharma in the third quarter worth about $1,512,000. Finally, Barclays PLC boosted its position in shares of Sutro Biopharma by 385.3% in the third quarter. Barclays PLC now owns 273,019 shares of the company’s stock worth $944,000 after buying an additional 216,757 shares during the period. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Sutro Biopharma Stock Performance

Shares of STRO opened at $1.87 on Wednesday. The company has a market capitalization of $154.20 million, a P/E ratio of -1.16 and a beta of 1.15. Sutro Biopharma, Inc. has a one year low of $1.51 and a one year high of $6.13. The stock has a 50-day moving average price of $1.93 and a 200 day moving average price of $3.04.

Analysts Set New Price Targets

Several brokerages have recently weighed in on STRO. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Sutro Biopharma in a research report on Monday, November 18th. Wells Fargo & Company decreased their target price on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a research report on Wednesday, December 11th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Sutro Biopharma in a research report on Tuesday, December 10th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.13.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.